Keskinsezer Mualla, Yazici Ahmet Bulent, Guney Eskiler Gamze, Hamarat Kaan Furkan, Davutoglu Onur, Yazici Esra
Department of Psychiatry, Faculty of Medicine, Sakarya University, 54290 Sakarya, Türkiye.
Department of Medical Biology, Faculty of Medicine, Sakarya University, 54290 Sakarya, Türkiye.
J Clin Med. 2024 Nov 24;13(23):7105. doi: 10.3390/jcm13237105.
We aimed to examine the relationship of Dopamine transporter (DAT) and vesicular monoamine transporter (VMAT-2) gene and protein levels with psychic experiences and other clinical parameters in individuals with Methamphetamine Use Disorder (MUD). This study included 50 males diagnosed with MUD and 50 males as a smoking control (SC) and nonsmoking control (NSC). Community Assessment of Psychic Experiences (CAPE) was administered to patients and controls; Addiction Profile Index, Treatment Motivation Questionnaire, and Substance Craving Scale were administered only to the patient group. DAT and VMAT2 gene and protein levels were determined in blood obtained from the controls and patient groups. CAPE positive, depressive, total, and distress scores were significantly higher in the patient group. DAT protein level and gene and protein levels were lower in the patient group compared to the controls. The gene expression level was higher in the patient group compared to the controls. There was no correlation between any clinical variables and expression levels. A low gene expression level could diagnose MUD with a 5% probability when NSCs were used as a reference. A high gene expression level could diagnose tobacco use disorder (TUD) with a 99.9% probability when NSCs were used as a reference. The patient group showed more psychic experiences than healthy people. The low expression of the gene was identified as a predictor of MUD, while the high expression of the gene was predictive of TUD.
我们旨在研究多巴胺转运体（DAT）和囊泡单胺转运体（VMAT-2）的基因及蛋白水平与甲基苯丙胺使用障碍（MUD）患者的精神体验及其他临床参数之间的关系。本研究纳入了50名被诊断为MUD的男性以及50名男性作为吸烟对照（SC）和非吸烟对照（NSC）。对患者和对照者进行了精神体验社区评估（CAPE）；仅对患者组进行了成瘾概况指数、治疗动机问卷和物质渴望量表评估。测定了对照组和患者组血液中DAT和VMAT2的基因及蛋白水平。患者组的CAPE阳性、抑郁、总分和痛苦得分显著更高。与对照组相比，患者组的DAT蛋白水平以及基因和蛋白水平更低。与对照组相比，患者组的基因表达水平更高。任何临床变量与表达水平之间均无相关性。以NSC作为参照时，低基因表达水平诊断MUD的概率为5%。以NSC作为参照时，高基因表达水平诊断烟草使用障碍（TUD）的概率为99.9%。患者组比健康人表现出更多的精神体验。基因的低表达被确定为MUD的一个预测指标，而基因的高表达可预测TUD。
